Cargando…

Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review

Systemic mastocytosis (SM) is a heterogeneous disease characterized by the expansion of mast cells in one or more tissues, frequently characterized by the presence of KITD816V mutation. The updated World Health Organization (WHO) classification of myeloid neoplasms recognizes SM with an associated h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barozzi, Enrico, Bucelli, Cristina, Grifoni, Federica Irene, Gianelli, Umberto, Iurlo, Alessandra, Cattaneo, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790034/ https://www.ncbi.nlm.nih.gov/pubmed/35096623 http://dx.doi.org/10.3389/fonc.2021.819097

Ejemplares similares

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
por: Iurlo, Alessandra, et al.
Publicado: (2019)

The Role of New Technologies in Myeloproliferative Neoplasms
por: Palumbo, Giuseppe A., et al.
Publicado: (2019)

Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib
por: Sciumè, Mariarita, et al.
Publicado: (2021)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
por: Cattaneo, Daniele, et al.
Publicado: (2021)

Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study
por: Bucelli, Cristina, et al.
Publicado: (2021)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
por: Pasquale, Raffaella, et al.
Publicado: (2022)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study
por: Cattaneo, Daniele, et al.
Publicado: (2021)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms
por: WU, HUANLING, et al.
Publicado: (2013)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review
por: Orofino, Nicola, et al.
Publicado: (2017)

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Tasleem, Azka, et al.
Publicado: (2021)

Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms
por: Hochman, Michael J., et al.
Publicado: (2021)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
por: Hermouet, Sylvie
Publicado: (2023)

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview
por: Kuendgen, Andrea, et al.
Publicado: (2021)

Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms
por: Ichimura, Shinya, et al.
Publicado: (2012)

Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
por: Clara, Joseph A., et al.
Publicado: (2016)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
por: Gerke, Margo B., et al.
Publicado: (2023)

Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms
por: Lim, Ken-Hong, et al.
Publicado: (2021)

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
por: Brune, Magdalena M., et al.
Publicado: (2021)

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms
por: O‘Hagan Henderson, Samantha, et al.
Publicado: (2021)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
por: Brecqueville, M, et al.
Publicado: (2011)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants
por: Sabattini, Elena, et al.
Publicado: (2021)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

New Perspectives on Polycythemia Vera: From Diagnosis to Therapy
por: Iurlo, Alessandra, et al.
Publicado: (2020)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
por: Iurlo, Alessandra, et al.
Publicado: (2021)

Towards a Therapeutic Reduction of Imatinib Refractory Myeloproliferative Neoplasm-Initiating Cells
por: Philips, Steven T., et al.
Publicado: (2013)

The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases
por: Pizzi, Marco, et al.
Publicado: (2021)

The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
por: Pettersson, Helna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pre0flvd65n3nbas9hpl4fv15i